GMP IPO Watch
Axis NIFTY Healthcare ETF
Axis Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.73% | +4.12% | 59 of 85 |
| 1M | +3.73% | +3.71% | 40 of 81 |
| 3M | -0.35% | -3.27% | 8 of 71 |
| 6M | +10.90% | +1.12% | 7 of 63 |
| YTD | +14.48% | -1.76% | 4 of 85 |
| 1Y | +13.26% | -0.73% | 5 of 53 |
| 2Y | +7.91% | +3.62% | 8 of 45 |
| 3Y | +21.08% | +12.97% | 5 of 35 |
| 5Y | +14.40% | +9.88% | 5 of 24 |
| INCEPTION | +13.81% | — | — |
Ranked among: Exchange Traded Funds (ETFs) - Equity ETF.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.50% | +23.93% | -14.01% | 62% | 25% |
| 6M | +7.10% | +32.46% | -15.50% | 64% | 26% |
| 1Y | +15.90% | +62.36% | -14.85% | 76% | 33% |
| 2Y | +19.17% | +37.97% | -2.10% | 98% | 45% |
| 3Y | +20.32% | +26.88% | +11.85% | 100% | 48% |
| 5Y | +13.22% | +14.41% | +11.84% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.97%
- Debt0.00%
- Cash0.03%
- Other0.00%
Market Cap Split
- Large Cap47.80%
- Mid Cap48.39%
- Small Cap3.80%
- Others0.01%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 39.39 | — |
| P/B | 5.49 | — |
| Price / Sales | 5.66 | — |
| Price / Cash Flow | 30.77 | — |
| Dividend Yield (%) | 0.62 | — |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 17.00% | -1.08% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 10.44% | +0.09% |
| Apollo Hospitals | Equity | 7.43% | -0.45% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 6.82% | +0.41% |
| Cipla | Pharmaceuticals & Biotechnology | 6.69% | -0.13% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 6.65% | +0.60% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 6.24% | -0.15% |
| Max Healthcare Institute | Equity | 6.12% | -0.55% |
| Lupin | Pharmaceuticals & Biotechnology | 4.36% | -0.21% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.08% | -0.01% |
| Fortis Healthcare | Equity | 3.55% | -0.52% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 3.11% | -0.10% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 2.75% | +0.07% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 2.54% | +0.04% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 2.51% | +0.15% |
View all 22 holdings
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.37% | +0.01% |
| Biocon | Pharmaceuticals & Biotechnology | 2.28% | -0.25% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 2.04% | — |
| Krishna Institute of Medical Sciences | Equity | 1.76% | — |
| Abbott | Pharmaceuticals & Biotechnology | 1.25% | +0.09% |
| Clearing Corporation of India Ltd | Net Current Assets | 0.32% | — |
| Net Receivables / (Payables) | Net Current Assets | -0.29% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.91 | 18.24 | Low Volatility |
| 3Y | 14.72 | 17.03 | Low Volatility |
| 5Y | 14.92 | 16.72 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.49 | -0.41 | Above Average |
| 3Y | 0.94 | -0.95 | Above Average |
| 5Y | 0.57 | 0.30 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.45 | 0.01 | Above Average |
| 3Y | 2.03 | 1.15 | Above Average |
| 5Y | 1.45 | 0.93 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.95 | 0.96 | Good Risk Adjusted Returns |
| 3Y | 0.99 | 0.96 | Poor Risk Adjusted Returns |
| 5Y | 0.99 | 0.95 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Tracking Difference
Versus Nifty Healthcare TRI, as of Sep 2026.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Aditya Birla Sun Life Silver ETF | +26.41% | +36.60% | — | +25.53% |
| Mirae Asset Nifty Metal ETF | +19.77% | — | — | +11.29% |
| Aditya Birla Sun Life Gold ETF | +17.03% | +31.14% | +23.34% | +11.72% |
| Aditya Birla Sun Life Nifty Healthcare ETF | +13.45% | +21.49% | +14.72% | +14.59% |
| Mirae Asset S&P 500 Top 50 ETF | +8.91% | +26.13% | +16.80% | +18.42% |
|
Zerodha Nifty Smallcap 100 ETF
Direct Plan
|
+4.45% | — | — | +5.77% |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | +3.81% | — | — | +2.07% |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | +3.57% | — | — | +1.24% |
| Mirae Asset Nifty India Manufacturing ETF | +2.84% | +18.00% | — | +16.06% |
| Axis Nifty500 Value 50 ETF | +1.84% | — | — | +11.04% |
More From Axis Asset Management Co. Ltd.
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
| Axis Silver ETF | +26.40% | +35.94% | — | +33.11% |
|
Axis Silver Fund of Fund
Direct Plan · Growth Option
|
+25.78% | +35.80% | — | +33.62% |
|
Axis Gold Fund
Direct Plan · Growth option
|
+16.88% | +30.78% | +23.12% | +10.32% |
| Axis Gold ETF | +16.64% | +30.81% | +23.30% | +11.67% |
|
Axis NASDAQ 100 US Specific Equity Passive FOF
Direct Plan · IDCW Option
|
+15.62% | +27.97% | — | +30.61% |
|
Axis Global Equity Alpha Fund of Fund
Direct Plan · Growth Option
|
+13.25% | +22.73% | +13.92% | +16.86% |
|
Axis India Manufacturing Fund
Direct Plan · IDCW Option
|
+13.04% | — | — | +18.81% |
|
Axis Global Innovation Fund of Fund
Direct Plan · IDCW Option
|
+9.94% | +22.97% | +11.52% | +12.36% |
|
Axis Innovation Fund
Direct Plan · Growth Option
|
+9.66% | +17.73% | +10.46% | +14.81% |
|
Axis Nifty Smallcap 50 Index Fund
Direct Plan · IDCW Option
|
+8.53% | +16.64% | — | +16.76% |
About This Scheme
Investment Objective
The investment objective of the Scheme is to provide returns before expenses that closely correspond to the total returns of the NIFTY Healthcare Index subject to tracking errors. However, there is no assurance or guarantee that the investment objective of the scheme will be achieved.
Stated Asset Allocation
Equity instruments covered by NIFTY Healthcare Index - (95%-100%), Debt & Money Market Instruments - (0%-5%)
Exit Load
N/A
Fund Managers
Mr. Nandik Malik and Mr. Rohit Gautam
Mr. Nandik Malik - Primary /Domestic Equities & Mr. Rohit Gautam - Assistant Fund Manager – Equity Passive
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.